A5011453731- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Biochemical and Molecular Research
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Gallbladder and Bile Duct Disorders
- Multiple and Secondary Primary Cancers
- Glioma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
Cleveland Clinic
2023-2025
Case Comprehensive Cancer Center
2020-2023
University Hospitals of Cleveland
2019-2022
University Hospitals Seidman Cancer Center
2013-2022
Case Western Reserve University
2007-2021
University of Florida Health
2008
Duke University
1998
University of Massachusetts Chan Medical School
1998
Vanderbilt University
1998
Adagrasib, an irreversible, selective KRASG12C inhibitor, may be effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients previously treated unresectable or metastatic cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four With a median follow-up 11.9 months, ORR 34.0%, disease...
Abstract PIK3CA encodes the p110α catalytic subunit of PI3K and is frequently mutated in human cancers, including ∼30% colorectal cancer. Oncogenic mutations render cancers more dependent on glutamine. Here we report that glutaminase inhibitor CB-839 preferentially inhibits xenograft growth PIK3CA-mutant, but not wild-type (WT), cancers. Moreover, combination 5-fluorouracil (5-FU) induces PIK3CA-mutant tumor regression models. treatment increased reactive oxygen species caused nuclear...
Pemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC). The combination and pemetrexed has also demonstrated efficacy. We conducted a randomized study to determine the optimal therapy.Patients with NSCLC no prior systemic received carboplatin (area under curve, 6), paclitaxel (200 mg/m2), (15 mg/kg) up four cycles. Patients without progression after cycles were randomly assigned mg/kg), (500 two agents. primary end point was...
131 Background: KRAS G12C mutations occur in 3%–4% of CRC cases and are associated with poor prognosis. In the phase 1/2 KRYSTAL-1 study (NCT03785249), at a median follow-up 11.9 months (mo), Ada (irreversible inhibitor ) combination Cetux (anti-EGFR antibody) demonstrated promising clinical activity (objective response rate [ORR] 34% per blinded independent central review [BICR] 43% investigator [INV]) was well tolerated patients (pts) previously treated -mutated mCRC. Based on these...
Abstract Background. Src, EphA2, and platelet-derived growth factor receptors α β are dysregulated in pancreatic ductal adenocarcinoma (PDAC). Dasatinib is an oral multitarget tyrosine kinase inhibitor that targets BCR-ABL, c-Src, c-KIT, receptor β, EphA2. We conducted a phase II, single-arm study of dasatinib as first-line therapy patients with metastatic PDAC. Methods. (100 mg twice day, later reduced to 70 day because toxicities) was orally administered continuously on 28-day cycle. The...
The administration of allogeneic natural killer (NK) cells following a lymphodepleting chemotherapy regimen is emerging as well-tolerated therapeutic approach in the management various malignancies. Contrary to expected complications T cell therapy, there remains no evidence graft-versus-host disease (GVHD) mediated by NK numerous clinical trials. On contrary, preclinical and studies suggest that do not induce GVHD fact may prevent its development hematopoietic transplantation (HCT). In this...
Most recurrences of early-stage colorectal cancer detected with current surveillance measures are widespread and incurable. Circulating tumor DNA (ctDNA) may facilitate earlier diagnosis recurrent improve cancer-related outcomes.Plasma from patients undergoing standard after definitive treatment for stage II/III was assayed COLVERA carcinoembryonic antigen (CEA) at a single time point. Results were correlated radiographic imaging. Assay performance, including sensitivity specificity...
Optimizing the well-being of oncology clinician has never been more important. Well-being is a critical priority for cancer organization because burnout adversely impacts quality care, patient satisfaction, workforce, and overall practice success. To date, 45% U.S. ASCO member medical oncologists report experiencing symptoms emotional exhaustion depersonalization. As COVID-19 pandemic remains widespread with periods outbreaks, recovery, response substantial personal professional consequences...
PURPOSE: Approximately 20% of caregivers (CGs) live > 1 hour away from the patient and are considered distance (DCGs) who often report higher distress anxiety than local CGs. The purpose this study was to test effectiveness an intervention aimed at reducing in DCGs patients with cancer. METHODS: This randomized controlled trial enrolled all cancer types were being seen monthly by oncologists outpatient clinics. There three arms delivered over a 4-month period: arm (a) received 4...
We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab patients RAS wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC).In this phase Ib/II study, was combined RASwt mCRC ≥ one prior line therapy for advanced disease. analyzed baseline on-treatment tumor tissues changes microenvironment (TME), using flow cytometry and multispectral immunofluorescence.Forty-four were evaluable efficacy. The study negative primary endpoint [overall response rate: 2.6%,...
2562 Background: Colorectal cancers (CRCs) harboring a PIK3CA mutation demonstrate glutamine dependency in both vitro and vivo models, including those known to be fluoropyrimidine (FP) resistant. CB-839 (CB) is an oral inhibitor of glutaminase, key enzyme metabolism. Preclinical studies further show that the combination CB FP superior either as single agent, can overcome resistance. We conducted phase I trial assess maximum tolerated dose limiting toxicities (DLTs) when given with...
TPS4578 Background: Neoadjuvant chemotherapy (NAC) with C prior to cystectomy prolongs survival and increases the cure rate in MIUC. Most MIUC patients, however, are not cured NAC or cisplatin ineligible. Both G have favorable immunomodulatory activity ability increase antigen presentation, inhibit reduce myeloid derived suppressor cells, prevent PD-1 dependent CD4+ T cell tolerization. Single agent antagonism P has been shown metastatic urothelial cancer. Hoosier Cancer Research Network...
Biliary tract cancers (BTC) have a limited prognosis even for localized cancers, emphasizing the importance of multidisciplinary management. NCCN guidelines recommend adjuvant chemotherapy (CT) +/- radiotherapy (RT) high-risk disease. We analyzed association between racial and ethnic category along with other demographic factors concordance to among patients following surgery BTC. Subjects were identified from National Cancer Database (NCDB) BTC who underwent found metastatic lymph nodes...
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utilizing pentostatin, cyclophosphamide, and rituximab (PCR) followed by consolidation course alemtuzumab. This enrolled 102 patients median age 64 years. Treatment consisted 6 cycles PCR alemtuzumab either 4 or 18 weeks depending on initial response to...
BACKGROUND The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors low thymidylate synthase (TS‐L) expression would have a higher response rate to combined 5‐fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those high TS (TS‐H) irinotecan (IROX) (IROX/Bev) be more effective FOLFOX/Bev in TS‐H tumors. METHODS protein was determined mCRC tissue. Patients TS‐L received FOLFOX/Bev, were randomly assigned receive either...
7166 Background: The prognosis of patients with ES-SCLC remains poor despite a high initial response to chemotherapy. Cooperative group trials have shown in general median survival 9 months and 1-year 35% (E7593). Thalidomide has been antiangiogenic activity preclinical models angiogenesis is biologically important SCLC. Methods: Patients who achieved partial or complete induction chemotherapy for were enrolled on multicenter phase 2 clinical trial. was given at fixed dose 200 mg orally...
2558 Background: Temozolomide (TMZ) is an alkylating agent that generates DNA adducts are repaired by direct and base excision repair mechanisms. Methoxyamine (MX, TRC-102) a small molecule potentiates TMZ binding to apurinic apyrimidinic sites after removal of N3-methyladenine N7-methylguanine, inhibiting site recognition apurinic/apyrimidinic (AP) endonuclease. We conducted phase I trial determine the maximum tolerated dose (MTD) dose-limiting toxicities (DLTs) intravenous MX when given...
Neoadjuvant chemotherapy (CT) is being utilized more frequently in patients diagnosed with localized pancreatic cancer. The role of additional neoadjuvant radiotherapy (RT) remains undefined. We explored outcomes associated RT the modern era.The National Cancer Database (2010-2017) was queried for clinical stage II-III adenocarcinoma who received multiagent systemic CT +/- RT. Demographics, pathologic outcomes, postoperative and overall survival were compared.A total 5245 included, whom 3123...